Search results
Results From The WOW.Com Content Network
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
Management of ulcerative colitis involves first treating the acute symptoms of the disease, then maintaining remission. Ulcerative colitis is a form of colitis , a disease of the intestine , specifically the large intestine or colon , that includes characteristic ulcers , or open sores, in the colon.
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, with Crohn's disease and ulcerative colitis (UC) being the principal types. [3] Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas UC primarily affects the colon ...
[22] [23] Inflammatory bowel disease resulted in 47,400 deaths in 2015, [24] and those with Crohn's disease have a slightly reduced life expectancy. [1] Onset of Crohn's disease tends to start in adolescence and young adulthood, though it can occur at any age. [25] [1] [3] [26] Males and females are affected roughly equally. [3]
Ulcerative colitis (UC) is one of the two types of inflammatory bowel disease (IBD), with the other type being Crohn's disease. [1] It is a long-term condition that results in inflammation and ulcers of the colon and rectum. [1] [7] The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood (hematochezia). [1]
Treatment initially involves the use of medications to eliminate infections (generally antibiotics) and reduce inflammation (generally aminosalicylate anti-inflammatory drugs and corticosteroids). Surgery may be required for complications such as obstructions, fistulae, abscesses , or if the disease does not respond to drugs within a reasonable ...
In 2019, a 25-year-old man presented with symptoms consistent with alcohol intoxication, including dizziness, slurred speech and nausea. He had no prior alcoholic drinks but had a blood alcohol level of 0.3 g/dL. The patient was given 100 mg of the antifungal fluconazole daily for 3 weeks, and his symptoms were resolved. [8]
Inflammatory Bowel Diseases is a monthly peer-reviewed medical journal covering all aspects of inflammatory bowel disease. It was established in 1995 and is published by Oxford University Press. [1] It is the official journal of the Crohn's & Colitis Foundation. The editor-in-chief is Fabio Cominelli (Case Western Reserve University). [2]